EUVIMEDSkopri EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Postbiotics as Next Generation Biotherapeutics Targeting the Gut–Immune–Metabolic Axis: An Integrative Review

Asad Abbas iD, Ralf Weiskirchen iD, Muhammad Bilal, Muhammad Khurram Afzal, Abdul Malik, Suhail Akhtar, Masooma Khan, Izma Rashid, Fatima Khalid, Shazia Akram iD, Anza Saleem, Stanley Irobekhian Reuben Okoduwa

Pharmaceuticals · 2026-07-28 · 19 (8) · 1184

DOI: 10.3390/ph19081184 ↗

At a glance

Übersichtsarbeit in Pharmaceuticals, published online on 2026-07-28. Written by Asad Abbas and 11 co-authors. Institution: Department of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan 60800, Pakistan. Cited 2 times so far (Crossref); 137 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The gut–immune–metabolic axis has emerged as a central regulator of human health, with growing evidence indicating that microbiota-derived metabolites improve gut microbial ecology, enhance intestinal barrier integrity, reduce systemic inflammation, and maintain metabolic homeostasis. This review synthesizes current mechanistic and clinical evidence on the role of postbiotics in regulating intestinal barrier integrity, immune responses, oxidative stress, and metabolic–endocrine homeostasis. The literature was identified through the PubMed/MEDLINE, Scopus, and Web of Science, integrating evidence from experimental, mechanistic, animal and clinical studies on the therapeutic potential of postbiotics to modulate the gut–immune–metabolic axis. Preclinical studies suggest that postbiotics may enhance epithelial barrier function by improving tight junction integrity through multiple pathways such as PI3K/Akt signaling, stimulating mucin-2 (MUC2) production, and reducing intestinal permeability. They modulate immune responses through interactions with Toll-like receptors, nucleotide-binding oligomerization domain receptors, and G-protein-coupled receptors (GPR41/43), influencing key signaling pathways, including NF-κB and Nrf2, and altering cytokine profiles, such as IL-10, TNF-α, and IFN-γ. Similarly, preclinical investigations have demonstrated that short-chain fatty acids (SCFAs) and other microbial metabolites may improve insulin sensitivity, regulate hepatic gluconeogenesis, stimulate glucagon-like peptide 1 (GLP-1) secretion, and modulate lipid metabolism through the FXR and TGR5 signaling pathways. Emerging human studies suggest potential benefits of postbiotics in regulating gut, immune, and metabolic health; nevertheless, clinical evidence remains limited and is influenced by variability in postbiotic composition, dosage, formulation, and metabolite profiles. Therefore, standardized production approaches and well-designed large-scale randomized clinical trials are required to confirm therapeutic efficacy and establish evidence-based applications of postbiotics.

Subjects

Author keywords

endocrine regulationgut barrier integrityimmunomodulationmetabolic syndromemicrobiota–host crosstalkoxidative stresspostbioticsshort-chain fatty acids

Authors and institutions

  • Department of Human Nutrition, Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan 60800, Pakistan.
  • Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, D-52074 Aachen, Germany.
  • Faculty of Food Science and Nutrition, Bahauddin Zakariya University, Multan 60800, Pakistan.
  • Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
  • Department of Biomedical Education and Data Science Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA.
  • Multan College of Nutritional Sciences, Multan Medical and Dental College, Multan 60000, Pakistan.

ORCID profiles: Asad Abbas, Ralf Weiskirchen, Shazia Akram

Cite

APA

Abbas, A., Weiskirchen, R., Bilal, M., Afzal, M. K., Malik, A., Akhtar, S., Khan, M., Rashid, I., Khalid, F., Akram, S., Saleem, A., & Okoduwa, S. I. R. (2026). Postbiotics as Next Generation Biotherapeutics Targeting the Gut–Immune–Metabolic Axis: An Integrative Review. Pharmaceuticals, 19(8), 1184. https://doi.org/10.3390/ph19081184

Vancouver

Abbas A, Weiskirchen R, Bilal M, Afzal MK, Malik A, Akhtar S, et al. Postbiotics as Next Generation Biotherapeutics Targeting the Gut–Immune–Metabolic Axis: An Integrative Review. Pharmaceuticals. 2026;19(8):1184. doi:10.3390/ph19081184

BibTeX
@article{Abbas2026,
  author = {Abbas, Asad and Weiskirchen, Ralf and Bilal, Muhammad and Afzal, Muhammad Khurram and Malik, Abdul and Akhtar, Suhail and Khan, Masooma and Rashid, Izma and Khalid, Fatima and Akram, Shazia and Saleem, Anza and Okoduwa, Stanley Irobekhian Reuben},
  title = {Postbiotics as Next Generation Biotherapeutics Targeting the Gut–Immune–Metabolic Axis: An Integrative Review},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {8},
  pages = {1184},
  doi = {10.3390/ph19081184}
}
Start for free →